The $25M Contract Nobody Is Talking About

One deal alone covers the entire valuation of this overlooked stock. And more contracts are already stacking up in Europe and the US.

Popular

Social Security whistleblower who claims DOGE mishandled Americans' sensitive data resigns from post

WASHINGTON (AP) — A Social Security official who has filed a whistleblower complaint alleging the Department of Government Efficiency officials Americans' sensitive information says he's resigning his post because of actions taken against him since making his complaint.

OpenAI and Meta say they're fixing AI chatbots to better respond to teens in distress

SAN FRANCISCO (AP) — Artificial intelligence chatbot makers OpenAI and Meta say they are adjusting how their chatbots respond to teenagers and other users asking questions about suicide or showing signs of mental and emotional distress.

The Next Palantir Moment Could Be Here - Ad

A $21M market cap company is landing multimillion-dollar contracts with banks and governments. With only 9.7M shares in the float, scarcity could spark explosive moves.

Trump's new CDC chief: A Washington health insider with a libertarian streak

WASHINGTON (AP) — President Donald Trump has picked Jim O’Neill, a former investor and critic of health regulations serving under Health Secretary Robert F. Kennedy Jr., to take control of the Centers for Disease Control and Prevention, following a tumultuous week in which the agency's director was forced out.

Cat in San Francisco euthanized after latest bird flu infection tied to raw pet food

Federal health officials are warning that certain lots of raw cat food may be contaminated after a pet cat in San Francisco that ate the food became infected with the virus and had to be euthanized.

Analysts Project This Stock Could Jump to $14 a Share. You Can Still Invest for $3.50. - Ad

The AI company making heart disease easier to detect is offering investors $3.50 investment units that include one convertible preferred share and one warrant, providing investors with access to 2 common shares. Based on analyst 1- year projections, that amounts to a near-term 500% return potential.

FDA Expands Krystal Biotech Vyjuvek's Label Allowing Newborns Access To Gene Therapy For Blistering Skin

The FDA approved Krystal Biotech's Vyjuvek label update, expanding treatment to newborns and offering flexible wound care based on real-world patient data.

Tempus AI Gains FDA Clearance For Updated Pixel To Boost Accuracy And Efficiency In Cardiac Imaging

Tempus AI's Tempus Pixel received FDA clearance for cardiac imaging updates, adding T1/T2 maps to enhance MR image analysis and diagnosis precision.

Why Are Wall Street Insiders Moving Their Money to This One Asset? - Ad

Something far more consequential for your money than tariffs is unfolding behind the scenes... Tucked inside this overlooked directive is a plan set to be executed for the first time in in U.S. history. One Stansberry Research's Senior Partner says it's set to trigger a rare window for potentially explosive gains in ONE asset immediately. (Not AI or crypto). Wall Street insiders are already positioning themselves... and he insists you should, too, before it's too late.

Novo Nordisk, maker of obesity drug Wegovy, to cut 9,000 jobs to sharpen focus, meet competition

FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk, maker of weight-loss drug Wegovy, said Wednesday it would cut 9,000 jobs, 5,000 of them in Denmark, in order to strengthen the company's focus on growth opportunities in obesity and diabetes medications.

PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment

BioMarin's Palynziq significantly lowered blood phenylalanine in teens with PKU, with nearly half reaching target levels in the Phase 3 study.

The Best Case for Gold, Ever - Ad

Gold has hit all-time highs, breaking $3,600 an ounce - but history shows it could be on the verge of its biggest bull run in over half a century... triggered by a likely major event, eerily similar to what happened in the 1970s. (It's NOT inflation or anything you're likely expecting.) Now, a top analyst says you can capture ALL of the upside without touching a risky miner or a boring exchange-traded fund. He sees extraordinary potential gains long term with very little risk.

Trump Admin Targets Medicaid Spending On Immigrants, Threatening Over $12 Billion California Program

The Trump administration is investigating Medicaid spending in California and other Democrat-led states over potential misuse in immigrant healthcare programs.

Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data

Skye Bioscience's latest data show nimacimab boosted tirzepatide's weight loss effects and reduced obesity treatment rebound risk.

This Gold Miner Has the Map, the Metal, and the Momentum - Ad

JPMorgan is forecasting that gold will push past $4,000, and this Nevada operation is positioned to benefit. Historical estimates show its property could hold around 1.8 million ounces of measured and indicated gold, backed by infrastructure and billionaire investors. The company's already producing, refining gold onsite and looking to expand. That's not a dream-stage story-that's a head start.

Trump administration agrees to restore health websites and data

NEW YORK (AP) — Federal officials have agreed to restore and science-related webpages and data under to a lawsuit settlement with doctors groups and other organizations who sued.

Why Is GSK Partner Wave Life Sciences Stock Trading Lower On Wednesday?

Wave Life Sciences shares early WVE-006 trial results in alpha-1 antitrypsin deficiency, reporting durable protein production and favorable safety.

The $25M Contract Nobody Is Talking About - Ad

One deal alone covers the entire valuation of this overlooked stock. And more contracts are already stacking up in Europe and the US.

Gold Alert: Extraordinary Upside in One Stock (Not a Miner) - Ad

Gold has hit all-time highs, breaking $3,600 an ounce - but history shows it could be on the verge of its biggest bull run in over half a century... triggered by a likely major event, eerily similar to what happened in the 1970s. (It's NOT inflation or anything you're likely expecting.) Now, a top analyst says you can capture ALL of the upside without touching a risky miner or a boring exchange-traded fund. He sees extraordinary potential gains long term with very little risk.

Johnson & Johnson Ends Rheumatoid Arthritis Drug Combo Program

Johnson & Johnson ended a Phase 2a study of nipocalimab in rheumatoid arthritis after no added benefit was seen, but remains confident in its market potential.

Why Is Movano Stock Surging 68% In After-Hours Trading?

Movano Inc. shares surged nearly 69% in after-hours trading after receiving a Nasdaq extension to maintain its listing, signaling renewed investor confidence.

"40% Crash Coming? Yes, But Not Like You Think..." - Ad

The global order is in chaos. And according to 40-year market veteran Dr. David Eifrig, the biggest controlled demolition of the old monetary order in history could now be here, too. That means if you don't take action today, your wealth could decline by 40%... (Yes, even your cash savings.)

Vor Bio's Investigational Drug Scores Phase 3 Win In Autoimmune Kidney Disease Trial

Vor Bio partner RemeGen reports Phase 3 success for telitacicept in IgA nephropathy, showing a 55% drop in proteinuria and plans for a China BLA filing.

From Ore to Gold Bars-This Nevada Mine Is Already Producing - Ad

Most juniors explore...Few actually produce. This one's already pouring gold thanks to infrastructure that would cost tens of millions to build today. With major land holdings and room to scale, it's one to watch. Discover the little known gold company that's already producing.

Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win

Argenx advances Vyvgart with strong trial data in seronegative gMG, driving growth projections and reinforcing its leadership in IgG-driven diseases.

CareDx Battles Reimbursement Uncertainty As Market Overlooks Long-Term Potential

CareDx, Inc. faces uncertainty with proposed reimbursement changes, but has long-term potential in the $8 billion transplant solutions market.

Is This Elon's Worst Nightmare? - Ad

Elon's empire looks doomed - crashing sales, lost tax credits, and media backlash. But behind the scenes, Tesla is about to unleash a breakthrough Forbes calls a "multi-trillion-dollar opportunity." It's not the end - it's the start of a 25,000% AI comeback.

BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up

BeOne Medicines will sell global Imdelltra royalties to Royalty Pharma for up to $950 million while retaining rights to other oncology programs with Amgen.

The Next Palantir Moment Could Be Here - Ad

A $21M market cap company is landing multimillion-dollar contracts with banks and governments. With only 9.7M shares in the float, scarcity could spark explosive moves.

Apply safety rules to more trains carrying flammable cargo, lawmakers urge

When a BNSF freight train carrying six cars of liquefied petroleum gas derailed near Manuelito, New Mexico, in 2024, the resulting fire shut down more than 100 miles of an interstate highway.

Students face new cellphone restrictions in 17 states as school year begins

Jamel Bishop is seeing a big change in his classrooms as he begins his senior year at Doss High School in Louisville, Kentucky, where cellphones are now banned during instructional time.

Analysts Project This Stock Could Jump to $14 a Share. You Can Still Invest for $3.50. - Ad

The AI company making heart disease easier to detect is offering investors $3.50 investment units that include one convertible preferred share and one warrant, providing investors with access to 2 common shares. Based on analyst 1- year projections, that amounts to a near-term 500% return potential.

Minnesota sues TikTok, alleging it preys on young people with addictive algorithms

ST. PAUL, Minn. (AP) — Minnesota on Tuesday joined a wave of , alleging the social media giant preys on young people with addictive algorithms that trap them into becoming compulsive consumers of its short videos.

Recommended

Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.

Copyright trendadvisor.net
Privacy Policy | Terms of Service